Collplant

About:

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs.

Website: http://www.collplant.com

Twitter/X: CollplantBio

Top Investors: Meitav Investment House, Pontifax, Docor International Management, Meitav Underwriting, Modgal Industries

Description:

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

Total Funding Amount:

$74.7M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Rehovot, HaMerkaz, Israel

Founded Date:

1981-01-01

Contact Email:

info(AT)collplant.com

Founders:

Number of Employees:

51-100

Last Funding Date:

2021-02-11

IPO Status:

Public

Industries:

© 2025 bioDAO.ai